Back to Results
First PageMeta Content
Macrolides / Tacrolimus / Transplantation medicine / Astellas Pharma / Immunosuppressive drug / Kidney transplantation / Transplant rejection / Organ transplantation / Heart transplantation / Medicine / Organ transplants / Immunosuppressants


September 19, 2007 Astellas Submitted a Response to the FDA Action Letter for FK506 Modified Release Formulation for Kidney Transplantation Japan, September 19, [removed]Astellas Pharma Inc. (headquarters: Tokyo, presiden
Add to Reading List

Document Date: 2008-09-18 20:50:47

Open Document

File Size: 25,76 KB

Share Result on Facebook

City

Tokyo / Deerfield / /

Company

Astellas Pharma US Inc. / Astellas Pharma Inc. / Astellas US / /

Country

Japan / United States / /

Event

FDA Phase / /

/

MedicalTreatment

liver transplant / Kidney Transplantation / kidney transplant / heart transplant / /

Organization

FDA / U.S. Food and Drug Administration / /

Person

Masafumi Nogimori / /

/

Position

president and CEO / /

Product

Prograf / FK506 / /

ProvinceOrState

Illinois / /

Technology

Transplantation / /

URL

http /

SocialTag